Ibandronic acid - Lanco Biosciences

Drug Profile

Ibandronic acid - Lanco Biosciences

Alternative Names: Ibadronate - Lanco Biosciences; LBS-101

Latest Information Update: 26 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lanco Biosciences
  • Class Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; Dimethylallyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Osteoporosis

Highest Development Phases

  • Preclinical Osteoporosis

Most Recent Events

  • 26 Aug 2016 Chemical structure information added
  • 12 Aug 2016 Ibandronic acid - Lanco Biosciences is available for licensing as of 12 Aug 2016. https://lancobio.com/
  • 12 Aug 2016 Preclinical trials in Osteoporosis in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top